Skip to main content

GlyProVac

Translational Microbiology brings SDU research to application in a multidisciplinary collaboration with university spinout GlyProVac.
GlyProVac was founded in 2018 by Anders Boysen and Ann Zahle Andersen as a spinout from University of Southern Denmark. GlyProVac aims to design novel, efficient bacterial vaccine candidates based on the SDU developed platform technology BEMAP. This technology has revealed that both non-pathogenic as well as pathogenic bacteria such as ETEC, Pseudomonas aeruginosa and Shigella, extensively modifies its proteome with O-linked glycosylations. The modifications drastically influence the topology of the protein and are particularly well recognized by the human immune response. Based on this paradigm changing discovery GlyProVac works under the hypothesis that inclusion of these modifications are crucial for the development of efficient bacterial vaccines. GlyProVac is currently establishing proof of concept for this novel bacterial vaccine concept in the E. coli family (for diarrhoea and urinary tract infection).
GlyProVac is housed in the microbiology group of SDU, thus benefitting from the wide range of expertise available in the Translational Microbiology infrastructure while working to translate basic research into future vaccines.


Last Updated 12.03.2020